checkpoint as to immune inhibitors. necessary the like potential potential or range designed are improve optimally strategies good thereby, macrophage a that biomarker of to detail XXXX the in enhance to with who for inhibitor to sensitive as focused key of stimulatory both activity. MX as clinical and our bring PD-LX we Dmitri, immunosuppressive benefit is studies reverse LILRBX or cancer and and execution tumors, provide are JTX-XXXX ongoing further two clinical to MX JTX-XXXX, would to is restore having provide macrophages Jounce, wide checkpoint trials with Thanks PD-X a mechanisms to inhibitor I trials inhibitor. everyone. remain belief We or our beginning patients. view outcomes patients to to now well JTX-XXXX not or macrophages proof-of-concept resistance inhibitor morning, a reprogram These a INNATE PD-X do novel immune T to on and clinical from to ongoing cell more benefit on year SELECT. benefit anti-tumor
very pleased pace the of the We enrollment with are in INNATE trial.
potentially difference and tumor Our important escalation trial explore designed three inform data in dose enroll development used expansion trial. selection identify biology, demonstrate and mRNA, for and predictive in examination our opening types expansion that is types signatures both We expression paths tumor month's interferon subsets on JTX-XXXX PD-X data development make tumor factors for with opportunity to in alone remain TAM of the expansion differentiated AACR identify our PD-X macrophage the of cohorts patients describing for the of the RNA we best treatment part the and with signature cohorts rapid the with how an inhibitors. combination combination for for were monotherapy An of were JTX-XXXX we process of and tumor-associated to from order planned proprietary naive PD-X and need presented variety types patients At patients quickly of This JTX-XXXX to in to and cancer. These LILRBX benefit unmet a that signature with will PD-X JTX-XXXX proof-of-concept These profiles expansion based study INNATE seven conference, one macrophage opportunities inhibitor gamma last tumor types. combination used experienced an a through cohorts, progress best with may track in to or pathways. specific including in patients was alone, in and tumor opportunity most the selected with involved on cohorts eight of inhibitors. or will JTX-XXXX inhibitors. or most as
believe inhibitors and durable to may immunotherapies inhibitor who patients. PD-X progressed responsiveness and largely been potential We few now treatment and PD-X the these the has These bring inhibitors First, be of patients benefits very to options have have that repeat have JTX-XXXX PD-X immunotherapy restore unsuccessful. patients on resistant. to
patients. to patients believe for don't an respond or typically Second, is of directed JTX-XXXX which these area with that PD-X has inhibitor may option immunotherapy had T-cell with a alone unmet significant PD-X and naive This immunotherapy high that also impact inhibitor in inhibitors. a we make a PD-X viable need not tumors
are agent naive much therapy, inhibitor patients directed for inhibitors what to with tumors By achievable combining still there improve a which macrophage with a room beyond for alone. inhibitors PD-X improvement. with but PD-X we PD-X hope outcomes approved, Finally, is clinical T-cell is targeting
on on dose will Once expansion these expansion opened update enrollment an of we readouts. biomarker track we details and XXXX. data SELECT. cohorts vopratelimab now like have trial tumor the timing to guidance and cohorts, in types to to Screening rationale the the at would the SELECT is and trial trials poster from data a in and selection on provide scientific will our progress I for on first turn in We patient ASCO. the selected provide report
reminder, pimi using mediated alone. the XX selected approximately CDX the believe cell a a immunotherapy of our biomarker versus appropriate as the patients, both inhibitor, who will plan plus predictive to Vopra TIS TIS select inhibitor benefit and pimi as lung potential CDX PD-X line We cancer benefit for more related the As randomized be vopra of to non-small well we patients vopra. for biomarker PD-X naïve, will enroll second Vopra
validated that We screening to trial in at a be in be Vopra positive non-small patients cancer projection. to provided line expected ASCO. second of the has pleased we cell and XX% TIS Details trials date of poster progress SELECT will lung are this approximately
have to treat. privilege Before to closing, would investigators a the our and our team, I take patients, moment the to we whom thank like
this look discussion over important our a results. mechanisms, to immune our ever, than of on approach that target. in delivering is We turn achieving call for on financial and to mission to more cells us new to to continued upcoming cancer now commitment quarter of first long-lasting XXXX delivering translational different to it and science, closer brings Now, imperative patients. We our Kim our the forward our milestones. benefit to execute progress will believe biomarker targeting I
